Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for non-medical reasons

References

• Bloom BS. Prevalence and economic effects of depression. Manag Care 2004; 13: 9–16
   PubMedGoogle Scholar
• Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289: 3095–3105
   PubMed Web of Science ®Google Scholar
• Kessler RC, Nelson CB, McGonagle KA, et al. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry Suppl 1996; 17–30
   PubMedGoogle Scholar
• Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000?. J Clin Psychiatry 2003; 64: 1465–1475
   PubMed Web of Science ®Google Scholar
• Davidson JR, Meltzer-Brody SE. The underrecognition and undertreatment of depression: what is the breadth and depth of the problem?. J Clin Psychiatry 1999; 60(Suppl 7)4–9, discussion 10-11
   PubMed Web of Science ®Google Scholar
• Bradvik L, Mattisson C, Bogren M, et al. Long-term suicide risk of depression in the Lundby cohort 1947-1997 – severity and gender. Acta Psychiatr Scand 2008; 117: 185–191
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM, Keller MB, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997; 277: 333–340
   PubMed Web of Science ®Google Scholar
• Panzarino PJ, Jr, Nash DB. Cost-effective treatment of depression with selective serotonin reuptake inhibitors. Am J Manag Care 2001; 7: 173–184
   PubMed Web of Science ®Google Scholar
• Frank L, Revicki DA, Sorensen SV, et al. The economics of selective serotonin reuptake inhibitors in depression: a critical review. CNS Drugs 2001; 15: 59–83
   PubMed Web of Science ®Google Scholar
• Peveler R, Kendrick T, Buxton M, et al. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine. Health Technol Assess 2005; 9: 1–134, iii
   PubMed Web of Science ®Google Scholar
• Revicki DA, Simon GE, Chan K, et al. Depression, health-related quality of life, and medical cost outcomes of receiving recommended levels of antidepressant treatment. J Fam Pract 1998; 47: 446–452
   PubMed Web of Science ®Google Scholar
• Burke WJ. Escitalopram. Expert Opin Investig Drugs 2002; 11: 1477–1486
   PubMed Web of Science ®Google Scholar
• Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63: 331–336
   PubMed Web of Science ®Google Scholar
• Murdoch D, Keam SJ. Spotlight on escitalopram in the management of major depressive disorder. CNS Drugs 2006; 20: 167–170
   PubMed Web of Science ®Google Scholar
• Gorwood P, Weiller E, Lemming O, et al. Escitalopram prevents relapse in older patients with major depressive disorder. Am J Geriatr Psychiatry 2007; 15: 581–593
   PubMed Web of Science ®Google Scholar
• Kornstein SG, Bose A, Li D, et al. Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial. J Clin Psychiatry 2006; 67: 1767–1775
   PubMed Web of Science ®Google Scholar
• Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004; 65: 44–49
   PubMed Web of Science ®Google Scholar
• Baldwin DS. Escitalopram: efficacy and tolerability in the treatment of depression. Hosp Med 2002; 63: 668–671
   PubMedGoogle Scholar
• Baldwin DS, Reines EH, Guiton C, et al. Escitalopram therapy for major depression and anxiety disorders. Ann Pharmacother 2007; 41: 1583–1592
   PubMed Web of Science ®Google Scholar
• Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr 2002; 7: 40–44
   PubMed Web of Science ®Google Scholar
• Lam RW, Andersen HF. The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis. Pharmacopsychiatry 2006; 39: 180–184
   PubMed Web of Science ®Google Scholar
• Lepola U, Wade A, Andersen HF. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 2004; 19: 149–155
   PubMed Web of Science ®Google Scholar
• Lepola UM, Loft H, Reines EH. Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003; 18: 211–217
   PubMed Web of Science ®Google Scholar
• Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005; 20: 131–137
   PubMed Web of Science ®Google Scholar
• Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004; 65: 1190–1196
   PubMed Web of Science ®Google Scholar
• Llorca PM, Fernandez JL. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation. Int J Clin Pract 2007; 61: 702–710
   PubMed Web of Science ®Google Scholar
• Kilts CD, Wade AG, Andersen HF, et al. Baseline severity of depression predicts antidepressant drug response relative to escitalopram. Expert Opin Pharmacother 2009; 10: 927–936
   PubMed Web of Science ®Google Scholar
• Kroenke K, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA 2001; 286: 2947–2955
   PubMed Web of Science ®Google Scholar
• Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998; 55: 1128–1132
   PubMed Web of Science ®Google Scholar
• Lin EH, Von Korff M, Katon W, et al. The role of the primary care physician in patients’ adherence to antidepressant therapy. Med Care 1995; 33: 67–74
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry 2008; 63: 699–704
   PubMed Web of Science ®Google Scholar
• Nelson JC. Managing treatment-resistant major depression. J Clin Psychiatry 2003; 64(Suppl 1)5–12
   PubMed Web of Science ®Google Scholar
• Dording CM, Mischoulon D, Petersen TJ, et al. The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists. Ann Clin Psychiatry 2002; 14: 143–147
   PubMedGoogle Scholar
• Fava M. Management of nonresponse and intolerance: switching strategies. J Clin Psychiatry 2000; 61(Suppl 2)10–12
   PubMed Web of Science ®Google Scholar
• Thase ME. Therapeutic alternatives for difficult-to-treat depression: a narrative review of the state of the evidence. CNS Spectr 2004; 9: 808–816, 818-821
   PubMed Web of Science ®Google Scholar
• Fava M, McGrath PJ, Sheu WP. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine. J Clin Psychopharmacol 2003; 23: 365–369
   PubMed Web of Science ®Google Scholar
• Nurnberg HG, Thompson PM, Hensley PL. Antidepressant medication change in a clinical treatment setting: a comparison of the effectiveness of selective serotonin reuptake inhibitors. J Clin Psychiatry 1999; 60: 574–579
   PubMed Web of Science ®Google Scholar
• Perahia DG, Quail D, Desaiah D, et al. Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques. J Clin Psychiatry 2008; 69: 95–105
   PubMed Web of Science ®Google Scholar
• Ruhe HG, Huyser J, Swinkels JA, et al. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 2006; 67: 1836–1855
   PubMed Web of Science ®Google Scholar
• Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004; 25: 119–142
   PubMedGoogle Scholar
• Wohlreich MM, Mallinckrodt CH, Watkin JG, et al. Immediate switching of antidepressant therapy: results from a clinical trial of duloxetine. Ann Clin Psychiatry 2005; 17: 259–268
   PubMedGoogle Scholar
• Miner CM, Brown EB, Gonzales JS, et al. Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression. J Clin Psychiatry 2002; 63: 232–240
   PubMed Web of Science ®Google Scholar
• Russell JM, Berndt ER, Miceli R, et al. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline. Am J Manag Care 1999; 5: 597–606
   PubMed Web of Science ®Google Scholar
• Armstrong EP, Skrepnek GH, Haim Erder M. Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder. Curr Med Res Opin 2007; 23: 251–258
   PubMed Web of Science ®Google Scholar
• Demyttenaere K, Hemels ME, Hudry J, et al. A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin Ther 2005; 27: 111–124
   PubMed Web of Science ®Google Scholar
• Fantino B, Moore N, Verdoux H, et al. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder. Int Clin Psychopharmacol 2007; 22: 107–115
   PubMed Web of Science ®Google Scholar
• Fernandez JL, Montgomery S, Francois C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics 2005; 23: 155–167
   PubMed Web of Science ®Google Scholar
• Francois C, Toumi M, Aakhus AM, et al. A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway. Eur J Health Econ 2003; 4: 12–19
   PubMedGoogle Scholar
• Hemels ME, Kasper S, Walter E, et al. Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression. Ann Pharmacother 2004; 38: 954–960
   PubMed Web of Science ®Google Scholar
• Kulp W, von der Schulenburg JM, Greiner W. Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany. Eur J Health Econ 2005; 6: 317–321
   PubMedGoogle Scholar
• Sorensen J, Stage KB, Damsbo N, et al. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care. Nord J Psychiatry 2007; 61: 100–108
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Valuck R, Saseen J, et al. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 2004; 18: 911–932
   PubMed Web of Science ®Google Scholar
• Wade AG, Toumi I, Hemels ME. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom. Clin Ther 2005; 27: 486–496
   PubMed Web of Science ®Google Scholar
• Khandker RK, Kruzikas DT, McLaughlin TP. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder. J Manag Care Pharm 2008; 14: 426–441
   PubMed Web of Science ®Google Scholar
• Wu E, Greenberg PE, Yang E, et al. Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population. Curr Med Res Opin 2008; 24: 2587–2595
   PubMed Web of Science ®Google Scholar
• Wu E, Greenberg P, Yang E, et al. Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants. Curr Med Res Opin 2008; 24: 2805–2813
   PubMed Web of Science ®Google Scholar
• McCombs JS, Luo M, Johnstone BM, et al. The use of conventional antipsychotic medications for patients with schizophrenia in a Medicaid population: therapeutic and cost outcomes over 2 years. Value Health 2000; 3: 222–231
   PubMedGoogle Scholar
• Blough DK, Madden CW, Hornbrook MC. Modeling risk using generalized linear models. J Health Econ 1999; 18: 153–171
   PubMed Web of Science ®Google Scholar
• Diehr P, Yanez D, Ash A, et al. Methods for analyzing health care utilization and costs. Annu Rev Public Health 1999; 20: 125–144
   PubMed Web of Science ®Google Scholar
• Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004; 161: 692–699
   PubMed Web of Science ®Google Scholar
• Bull SA, Hunkeler EM, Lee JY, et al. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother 2002; 36: 578–584
   PubMed Web of Science ®Google Scholar